Design, synthesis and biological evaluation of 3',4',5'-trimethoxy flavonoid benzimidazole derivatives as potential anti-tumor agents. 2018

Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
Institute of Pharmacy and Pharmacology , Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study , University of South China , Hengyang , China . Email: 2393628359@qq.com ; Email: tgtzq@163.com.

A series of 3',4',5'-trimethoxy flavonoids with benzimidazole linked by different chain alkanes have been designed and synthesized. The potential activity of these compounds as anti-tumor agents was evaluated by cytotoxicity assay in MGC-803 (human gastric cancer), MCF-7 (human breast cancer), HepG-2 (human hepatoma) and MFC (mouse gastric cancer) tumor cell lines. Among them, compound 15 7-(3-(2-chloro-1H-benzo[d]imidazol-1-yl)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one displayed the most potent antiproliferative activity, with IC50 values of 20.47 ± 2.07, 43.42 ± 3.56, 35.45 ± 2.03 μM and 23.47 ± 3.59 μM, respectively. The flow cytometry (FCM) results showed that compound 15 caused the cell cycle to be arrested in G1 phase and induced apoptosis of MFC cells in a dose-dependent manner. In addition, compound 15 exhibited a significant inhibitory effect on tumor growth in vivo. All the results outlined the great potential of compound 15 for further exploitation as anti-tumor agent.

UI MeSH Term Description Entries

Related Publications

Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
November 2021, Drug development research,
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
March 2020, Bioorganic chemistry,
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
August 2018, Molecules (Basel, Switzerland),
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
October 2016, European journal of medicinal chemistry,
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
August 2020, Natural product research,
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
December 2013, Bioorganic & medicinal chemistry,
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
January 2023, Drug design, development and therapy,
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
August 2021, RSC medicinal chemistry,
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
August 2018, European journal of medicinal chemistry,
Zhe Wang, and Xiangping Deng, and Runde Xiong, and Shujuan Xiong, and Juan Liu, and Xuan Cao, and Xiaoyong Lei, and Yanming Chen, and Xing Zheng, and Guotao Tang
December 2019, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!